Results 101 to 110 of about 2,661,263 (289)

Therapeutic Opportunity in Innate Immune Response Induction by Oncogene-Targeted Drugs [PDF]

, 2019
Daniel J Sisler, Lynn E. Heasley
openalex   +1 more source

FAM83A: A Prognostic Biomarker and Its Correlation with Immune Infiltration in Lung Adenocarcinoma [PDF]

, 2022
Xue Sun, Lihong Bai, Peihang Xu, Yukun Kuang, Yifan Zheng, Jiyu Wang, Zi-Mu Li, Run-Jing Gan, Kejing Tang   +8 more
openalex   +1 more source

Foreign Sovereign Immunity, Individual Officials, and Human Rights Litigation [PDF]

, 2010
For thirty years, international human rights litigation in U.S. courts has developed with little attention to a lurking doctrinal objection to the entire enterprise.
Bradley, Curtis A., Goldsmith, Jack L.
core   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Immune class regulation as an integrated response of factors related to host, stimulus and context [PDF]

, 2018
S Prakash
openalex   +1 more source

The Yonkers Case: Separation of Powers as a Yardstick for Determining Official Immunity [PDF]

, 1989
The author examines the application of the official immunity doctrine to a situation where a federal district court issued contempt citations to local legislators in Yonkers who refused to pass legislation as required by a consent decree.
Walsh, Amy
core   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

Early immune development [PDF]

, 2018
Hannah Stower
openalex   +1 more source

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

Exploiting TCR Repertoire Analysis to Select Therapeutic TCRs for Cancer Immunotherapy

Cells
Over the past decade, numerous innovative immunotherapy strategies have transformed the treatment of cancer and improved the survival of patients unresponsive to conventional chemotherapy and radiation therapy. Immune checkpoint inhibition approaches aim
Ursule M. Demaël, Thunchanok Rirkkrai, Fatma Zehra Okus, Andreas Tiffeau-Mayer, Hans J. Stauss   +4 more
doaj   +1 more source